Despite these high expectations and demands for its therapeutic effects, many studies found that the use of GLP-1 RA was associated with an increased risk of thyroid cancer [8], pancreatitis [9,10], gastroparesis, bowel obstruction [10], or biliary diseases [11]. This evidence concerns the gene GLP1R and pancreatitis.